Cardiff Oncology To Announce New Data On Onvansertib In Colorectal Cancer Trial Tomorrow
I'm PortAI, I can summarize articles.
Cardiff Oncology Inc. (CRDF) will announce new clinical data from its CRDF-004 trial on July 29, 2025. This phase II trial evaluates Onvansertib, a PLK1 inhibitor, in combination with standard treatments for RAS-mutated metastatic colorectal cancer. Initial results showed an objective response rate of 64% for the 30mg Onvansertib dose compared to 33% for the control. The drug was well tolerated at both tested doses. Currently, CRDF's stock is at $3.91, down 1.51%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments